Lurbinectedin is a relatively new drug that has been studied for its efficacy in treating various types of cancer. However, there is limited information available on its long-term use.

According to the Drug Patent Watch [1], Lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer, which indicates that it is intended to treat rare diseases or disorders. This status provides incentives for drug manufacturers to develop and market drugs for these conditions. However, this does not necessarily indicate that the drug has been studied for long-term use.

A study published in the Journal of Clinical Oncology [2] evaluated the efficacy and safety of lurbinectedin in patients with small cell lung cancer. The study found that lurbinectedin demonstrated promising antitumor activity and was generally well-tolerated by patients. However, the study only followed patients for a maximum of 24 weeks, which is a relatively short period of time.

Another study published in the journal Cancers [3] evaluated the potential of lurbinectedin as a treatment for ovarian cancer. The study found that lurbinectedin showed significant antitumor activity in preclinical models of ovarian cancer, but did not provide information on the long-term use of the drug.

Overall, while lurbinectedin has shown promise in treating various types of cancer, there is limited information available on its long-term use. Further studies are needed to evaluate the safety and efficacy of the drug over extended periods of time.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/35427834/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271468/